Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.

Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00733-19. doi: 10.1128/AAC.00733-19. Print 2019 Sep.

PMID:
31209013
2.

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. doi: 10.1128/AAC.00470-19. Print 2019 Jun.

PMID:
30962331
3.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00388-19. doi: 10.1128/AAC.00388-19. Print 2019 Jun.

PMID:
30936097
4.

Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.

Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, Nuermberger E, Andries K.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e00007-19. doi: 10.1128/AAC.00007-19. Print 2019 Apr.

5.

In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.

Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02623-18. doi: 10.1128/AAC.02623-18. Print 2019 Mar.

6.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

7.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF, Guo H, Chang YS, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, Pillay L, Bester LA, Singh SD, Chaisson RE, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00636-18. doi: 10.1128/AAC.00636-18. Print 2018 Jul.

8.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

9.

Non-classical transpeptidases yield insight into new antibacterials.

Kumar P, Kaushik A, Lloyd EP, Li SG, Mattoo R, Ammerman NC, Bell DT, Perryman AL, Zandi TA, Ekins S, Ginell SL, Townsend CA, Freundlich JS, Lamichhane G.

Nat Chem Biol. 2017 Jan;13(1):54-61. doi: 10.1038/nchembio.2237. Epub 2016 Nov 7.

10.

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.

Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH.

J Antimicrob Chemother. 2017 Feb;72(2):455-461. doi: 10.1093/jac/dkw417. Epub 2016 Oct 25.

PMID:
27798204
11.

Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.

Swanson RV, Ammerman NC, Ngcobo B, Adamson J, Moodley C, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2864-9. doi: 10.1128/AAC.00177-16. Print 2016 May.

12.

Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.

Kubler A, Larsson C, Luna B, Andrade BB, Amaral EP, Urbanowski M, Orandle M, Bock K, Ammerman NC, Cheung LS, Winglee K, Halushka M, Park JK, Sher A, Friedland JS, Elkington PT, Bishai WR.

J Infect Dis. 2016 Feb 15;213(4):618-27. doi: 10.1093/infdis/jiv458. Epub 2015 Sep 27.

13.

Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.

Kling A, Lukat P, Almeida DV, Bauer A, Fontaine E, Sordello S, Zaburannyi N, Herrmann J, Wenzel SC, König C, Ammerman NC, Barrio MB, Borchers K, Bordon-Pallier F, Brönstrup M, Courtemanche G, Gerlitz M, Geslin M, Hammann P, Heinz DW, Hoffmann H, Klieber S, Kohlmann M, Kurz M, Lair C, Matter H, Nuermberger E, Tyagi S, Fraisse L, Grosset JH, Lagrange S, Müller R.

Science. 2015 Jun 5;348(6239):1106-12. doi: 10.1126/science.aaa4690.

PMID:
26045430
14.

Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.

Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, Moodley S, Mgaga Z, Tapley A, Bester LA, Singh S, Grosset JH, Almeida DV.

Antimicrob Agents Chemother. 2015;59(6):3042-51. doi: 10.1128/AAC.00260-15. Epub 2015 Mar 9.

15.

Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35. doi: 10.1128/AAC.04841-14. Epub 2015 Jan 26.

16.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):869-74. doi: 10.1073/pnas.1416951112. Epub 2015 Jan 5.

17.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH.

Mycobact Dis. 2014 May 5;4:145.

18.

Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation.

Kübler A, Luna B, Larsson C, Ammerman NC, Andrade BB, Orandle M, Bock KW, Xu Z, Bagci U, Mollura DJ, Marshall J, Burns J, Winglee K, Ahidjo BA, Cheung LS, Klunk M, Jain SK, Kumar NP, Babu S, Sher A, Friedland JS, Elkington PT, Bishai WR.

J Pathol. 2015 Feb;235(3):431-44. doi: 10.1002/path.4432. Epub 2014 Oct 6.

19.

Indoleamides are active against drug-resistant Mycobacterium tuberculosis.

Lun S, Guo H, Onajole OK, Pieroni M, Gunosewoyo H, Chen G, Tipparaju SK, Ammerman NC, Kozikowski AP, Bishai WR.

Nat Commun. 2013;4:2907. doi: 10.1038/ncomms3907.

20.

Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207).

Grosset JH, Ammerman NC.

Expert Rev Anti Infect Ther. 2013 Jul;11(7):649-51. doi: 10.1586/14787210.2013.811848.

PMID:
23879605
21.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A.

Am J Respir Crit Care Med. 2013 Sep 1;188(5):608-12. doi: 10.1164/rccm.201304-0753OC.

22.

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR.

Am J Respir Crit Care Med. 2013 Sep 1;188(5):600-7. doi: 10.1164/rccm.201304-0650OC.

23.

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.

Maiga M, Ammerman NC, Maiga MC, Tounkara A, Siddiqui S, Polis M, Murphy R, Bishai WR.

J Infect Dis. 2013 Aug 1;208(3):512-9. doi: 10.1093/infdis/jit187. Epub 2013 May 2. Erratum in: J Infect Dis. 2015 Jan 15;211(2):333.

24.

Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.

Onajole OK, Pieroni M, Tipparaju SK, Lun S, Stec J, Chen G, Gunosewoyo H, Guo H, Ammerman NC, Bishai WR, Kozikowski AP.

J Med Chem. 2013 May 23;56(10):4093-103. doi: 10.1021/jm4003878. Epub 2013 May 3.

PMID:
23611124
25.

Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

J Antimicrob Chemother. 2013 Mar;68(3):659-65. doi: 10.1093/jac/dks421. Epub 2012 Nov 5.

26.

Rv2190c, an NlpC/P60 family protein, is required for full virulence of Mycobacterium tuberculosis.

Parthasarathy G, Lun S, Guo H, Ammerman NC, Geiman DE, Bishai WR.

PLoS One. 2012;7(8):e43429. doi: 10.1371/journal.pone.0043429. Epub 2012 Aug 31.

27.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27.

28.

Surface proteome analysis and characterization of surface cell antigen (Sca) or autotransporter family of Rickettsia typhi.

Sears KT, Ceraul SM, Gillespie JJ, Allen ED Jr, Popov VL, Ammerman NC, Rahman MS, Azad AF.

PLoS Pathog. 2012;8(8):e1002856. doi: 10.1371/journal.ppat.1002856. Epub 2012 Aug 9.

29.

Gene expression of Mycobacterium tuberculosis putative transcription factors whiB1-7 in redox environments.

Larsson C, Luna B, Ammerman NC, Maiga M, Agarwal N, Bishai WR.

PLoS One. 2012;7(7):e37516. doi: 10.1371/journal.pone.0037516. Epub 2012 Jul 19.

30.

TolC-dependent secretion of an ankyrin repeat-containing protein of Rickettsia typhi.

Kaur SJ, Rahman MS, Ammerman NC, Beier-Sexton M, Ceraul SM, Gillespie JJ, Azad AF.

J Bacteriol. 2012 Sep;194(18):4920-32. doi: 10.1128/JB.00793-12. Epub 2012 Jul 6.

31.

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR.

J Infect Dis. 2012 Jun;205(11):1705-8. doi: 10.1093/infdis/jis269. Epub 2012 Apr 3. Erratum in: J Infect Dis. 2015 Jul 15;212(2):338. Dosage error in article text.

32.

Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis.

Lee JH, Ammerman NC, Nolan S, Geiman DE, Lun S, Guo H, Bishai WR.

Nat Commun. 2012 Mar 20;3:753. doi: 10.1038/ncomms1724.

33.

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.

Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR.

PLoS One. 2012;7(2):e30749. doi: 10.1371/journal.pone.0030749. Epub 2012 Feb 3.

34.

Functional characterization of a phospholipase A(2) homolog from Rickettsia typhi.

Rahman MS, Ammerman NC, Sears KT, Ceraul SM, Azad AF.

J Bacteriol. 2010 Jul;192(13):3294-303. doi: 10.1128/JB.00155-10. Epub 2010 Apr 30.

35.

A typhus group-specific protease defies reductive evolution in rickettsiae.

Ammerman NC, Gillespie JJ, Neuwald AF, Sobral BW, Azad AF.

J Bacteriol. 2009 Dec;191(24):7609-13. doi: 10.1128/JB.01077-09. Epub 2009 Oct 9.

36.

An anomalous type IV secretion system in Rickettsia is evolutionarily conserved.

Gillespie JJ, Ammerman NC, Dreher-Lesnick SM, Rahman MS, Worley MJ, Setubal JC, Sobral BS, Azad AF.

PLoS One. 2009;4(3):e4833. doi: 10.1371/journal.pone.0004833. Epub 2009 Mar 12.

37.

Louse- and flea-borne rickettsioses: biological and genomic analyses.

Gillespie JJ, Ammerman NC, Beier-Sexton M, Sobral BS, Azad AF.

Vet Res. 2009 Mar-Apr;40(2):12. doi: 10.1051/vetres:2008050. Epub 2008 Nov 28. Review.

38.

Laboratory maintenance of Rickettsia rickettsii.

Ammerman NC, Beier-Sexton M, Azad AF.

Curr Protoc Microbiol. 2008 Nov;Chapter 3:Unit 3A.5. doi: 10.1002/9780471729259.mc03a05s11.

39.

Growth and maintenance of Vero cell lines.

Ammerman NC, Beier-Sexton M, Azad AF.

Curr Protoc Microbiol. 2008 Nov;Appendix 4:Appendix 4E. doi: 10.1002/9780471729259.mca04es11.

40.

Characterization of Sec-translocon-dependent extracytoplasmic proteins of Rickettsia typhi.

Ammerman NC, Rahman MS, Azad AF.

J Bacteriol. 2008 Sep;190(18):6234-42. doi: 10.1128/JB.00794-08. Epub 2008 Jul 18.

41.

Plasmids and rickettsial evolution: insight from Rickettsia felis.

Gillespie JJ, Beier MS, Rahman MS, Ammerman NC, Shallom JM, Purkayastha A, Sobral BS, Azad AF.

PLoS One. 2007 Mar 7;2(3):e266. Review.

42.

Molecular differentiation of metastriate tick immatures.

Anderson JM, Ammerman NC, Norris DE.

Vector Borne Zoonotic Dis. 2004 Winter;4(4):334-42.

43.

Spotted-fever group Rickettsia in Dermacentor variabilis, Maryland.

Ammerman NC, Swanson KI, Anderson JM, Schwartz TR, Seaberg EC, Glass GE, Norris DE.

Emerg Infect Dis. 2004 Aug;10(8):1478-81.

Supplemental Content

Loading ...
Support Center